Hema Now | Episode 24
In this episode, host Jonathan Sackier is joined by Andrew Dunbar, Assistant Professor in the Department of Hematopoietic Biology and Malignancy at the University of Texas MD Anderson Cancer Center, Houston, USA. Dunbar discusses his research into myeloproliferative neoplasms, what drives disease progression and resistance, and promising targets for treatment, while reflecting on the mission of his lab and what lies ahead for the field.
Andrew Dunbar
Andrew Dunbar is the Assistant Professor in the Department of Hematopoietic Biology and Malignancy at the University of Texas MD Anderson Cancer Center, Houston, USA.
His work focuses on the study of clonal evolution, fibrosis progression, and targeted therapy resistance in myeloproliferative neoplasms and other myeloid blood cancers.
Timestamps
00:00 – Introduction
02:29 – One thing people should know about myeloproliferative neoplasms
05:01 – Dunbar’s background and research focus
08:00 – What would Dunbar do if not science and medicine?
10:24 – The basics of myeloproliferative neoplasms
14:30 – Myeloproliferative neoplasm diagnosis and treatment
16:49 – What drives disease progression and resistance?
18:30 – The mission of Dunbar’s lab
21:23 – Development of AJ1-11095
22:54 – Balancing the complexity of disease modelling with urgent clinical needs
24:03 – Promising targets and pathways
26:35 – What’s on the horizon?
28:40 – Three wishes
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ
